Target intelligence / Profile preview

Glutamate receptor ionotropic, kainate (KAR)

Target
KAR
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel, Ionotropic glutamate receptor
01

Overview

Glutamate receptor ionotropic, kainate (KAR) is a member of the ionotropic glutamate receptor family, functioning as a ligand-gated cation channel primarily in the central nervous system. KARs assemble as tetramers composed of five possible subunits (GluK1–GluK5) and mediate excitatory neurotransmission upon activation by glutamate or exogenous agonists like kainic acid. KARs play a key role in both fast synaptic transmission and the modulation of synaptic plasticity, and are expressed postsynaptically as modulators of excitation and presynaptically as regulators of neurotransmitter release. Structural and functional diversity among KAR subunits enable distinct roles in neuronal development, circuit formation, and pathology. Dysregulation and altered KAR function contribute to neurological and psychiatric diseases including epilepsy, depression, schizophrenia, and neurodegenerative diseases. KARs are considered important therapeutic targets, with ongoing research into agonists, antagonists, and allosteric modulators for potential interventions.

Other names
Kainate receptorKainic acid receptorIonotropic glutamate receptor, kainate subtypeGluK1–GluK5GluR5–GluR7KA1, KA2
02

Mechanism of action

Agonists (e.g., kainic acid, glutamate): activate the receptor and open the cation channel, resulting in depolarization and excitatory neurotransmission. Antagonists: block receptor activation by competing with agonist binding, inhibiting channel opening. Positive allosteric modulators: enhance receptor activity or prolong channel opening, often by stabilizing open or non-desensitized conformations.

03

Biological functions

Excitatory neurotransmissionSignal transductionSynaptic transmissionModulation of neuronal circuitsSynaptic plasticity
04

Disease associations

Neurodegenerative disease (Alzheimer’s, Parkinson’s)EpilepsyDepressionSchizophreniaAnxietyAutism spectrum disorderStroke
05

Safety considerations

Excitotoxicity (overactivation can lead to neuronal injury/death), relevant in stroke and neurodegenerative diseasesSeizures and epileptic activity (overstimulation)Neuropsychiatric side effects (modulation can affect mood, cognition, behavior)Off-target effects due to similarity with other ionotropic glutamate receptors (e.g., AMPA, NMDA receptors)
06

Interacting drugs

Kainic acid (agonist)

4 more in the full profile.

07

Biomarkers

Expression levels of KAR subunits (GluK1–GluK5) in CNS tissue are studied as markers for excitatory neurotransmission or disease states (e.g., epilepsy, neurodegeneration, psychiatric disorders), but currently they are not established clinical biomarkersNo standardized patient selection biomarkers for KAR-targeted therapeutics have been validated in clinical practice

Beyond the preview

Go deeper on Glutamate receptor ionotropic, kainate (KAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate receptor ionotropic, kainate (KAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call